RE:RE:RE:RE:RE:CZO Smallcap Discoveries Condference Oct 11, 2023
boazklinghorn wrote: THe worst part for me is listening to all the old stuff. IF you are hearing this pitch for the first time it might sound pretty good but for the tenth time to hear the same promises even the same wording from years ago is just painful. THe "Montreal heart institute" and "THe new kid on the block" THe Aveeno connection and on and on nothing has changed in 5 years
"THe worst part for me is listening to all the old stuff." That means they haven't pivoted to other business. It is a demonstration of confidence in the company's endgoals.
"THe "Montreal heart institute""
The avenanthramide clinical trial has never been expected imminently with dosing expected this month.
"THe new kid on the block"
The construction of the 5X scale-up PGX plant is expected this year. They have collaborations with the top two yeast beta glucan producers that control 80% of the market. The PGX-YBG clinical trial just required a 6 month toxicology study before regulatory submission. You con't conduct a toxicology study if everything else isn't expected to be positive.
CZO expects it will launch its dry beta glucan shortly.